8SV1 Stock Overview
Does not have any significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
WPD Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.011 |
| 52 Week High | CA$0.078 |
| 52 Week Low | CA$0.011 |
| Beta | 1.23 |
| 11 Month Change | 0% |
| 3 Month Change | -26.67% |
| 1 Year Change | -50.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8SV1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 0.8% |
| 1Y | -50.0% | -18.3% | 8.6% |
Return vs Industry: 8SV1 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 8SV1 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 8SV1 volatility | |
|---|---|
| 8SV1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8SV1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 8SV1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 19 | Mariusz Olejniczak | www.wpdpharmaceuticals.com |
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company’s drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML.
WPD Pharmaceuticals Inc. Fundamentals Summary
| 8SV1 fundamental statistics | |
|---|---|
| Market cap | €3.82m |
| Earnings (TTM) | -€3.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs 8SV1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8SV1 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$1.97k |
| Gross Profit | -CA$1.96k |
| Other Expenses | CA$4.86m |
| Earnings | -CA$4.86m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.043 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -14.4% |
How did 8SV1 perform over the long term?
See historical performance and comparison